Practice 5 structured short- and long-answer medical questions on Weekly Year 2: Microbiology Exam - May 15, 2026 (Sections B & C). Review model answers for...
Answer: Gram-positive bacteria possess a thick peptidoglycan layer external to the cytoplasmic membrane, often interspersed with teichoic acids. This thick layer retains the crystal violet stain, resulting in a purple Gram stain. Gram-negative bacteria have a thinner peptidoglycan layer located within the periplasmic space, enclosed by an outer membrane. This outer membrane contains lipopolysaccharide (LPS), which acts as an endotoxin and contributes to resistance against certain antibiotics (e.g., lysozyme) by forming a barrier. The thin peptidoglycan layer of Gram-negative bacteria does not retain crystal violet and is decolorized, counterstained pink by safranin. The presence of the outer membrane in Gram-negative bacteria significantly impacts antibiotic penetration, making them more resistant to some drugs that target the cell wall synthesis, while Gram-positive bacteria are generally more susceptible to penicillin-based antibiotics that inhibit peptidoglycan synthesis.
Answer: Antiviral medications work by interfering with specific stages of the viral life cycle. 1. **Nucleoside/Nucleotide Analogs (e.g., Acyclovir, Tenofovir):** These drugs mimic natural nucleosides or nucleotides. Once phosphorylated intracellularly, they are incorporated into the viral DNA or RNA by viral polymerases, leading to chain termination or the creation of faulty genetic material. Acyclovir is used to treat herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Tenofovir is a key component in the treatment of HIV and Hepatitis B. 2. **Protease Inhibitors (e.g., Ritonavir, Saquinavir):** These drugs block viral proteases, enzymes essential for cleaving viral polyproteins into functional viral proteins during replication. Without these functional proteins, new virions cannot assemble correctly. Protease inhibitors are primarily used in combination therapy for HIV infection to prevent the development of drug resistance.
Answer: Biofilms are complex, structured communities of bacteria embedded in a self-produced matrix of extracellular polymeric substances (EPS). This matrix, composed of polysaccharides, proteins, and nucleic acids, provides structural integrity and protects the bacteria from environmental stresses, including host immune defenses and antimicrobial agents. Significance in pathogenesis: Biofilms can adhere to host tissues or medical devices, leading to persistent infections that are difficult to eradicate (e.g., on prosthetic valves, urinary catheters, chronic wounds). The altered metabolic state of bacteria within biofilms also contributes to increased virulence and resistance. Treatment challenges: Bacteria within biofilms exhibit significantly reduced susceptibility to antibiotics (up to 1000-fold increase in resistance) compared to their planktonic counterparts. This is due to several factors: reduced penetration of antibiotics into the biofilm matrix, slower growth rates of bacteria within the biofilm (making them less susceptible to cell wall-targeting antibiotics), and altered gene expression leading to increased production of efflux pumps and stress response mechanisms. Eradicating biofilm-associated infections often requires prolonged antibiotic courses, high doses, or combination therapies, and sometimes surgical removal of infected material.
Answer: The innate immune system is the body's first line of defense against bacterial infections. It provides a rapid, non-specific response. Key mechanisms include: 1. **Phagocytosis:** Professional phagocytes like neutrophils and macrophages engulf and destroy bacteria. This process is enhanced by opsonization, where bacteria are coated with antibodies or complement proteins, making them more easily recognized by phagocytes. 2. **Complement System:** This is a cascade of plasma proteins that, when activated, can lead to direct lysis of bacteria (via the membrane attack complex), opsonization of bacteria to enhance phagocytosis, and chemotaxis of inflammatory cells to the site of infection. Other examples include antimicrobial peptides (e.g., defensins) that disrupt bacterial membranes, and pattern recognition receptors (PRRs) on immune cells that recognize conserved microbial molecules (PAMPs).
Answer: Pathogenesis of Staphylococcus aureus Community-Acquired Pneumonia (CAP): * **Entry:** S. aureus typically gains access to the lungs via aspiration of oropharyngeal secretions, or hematogenous spread from a distant site of infection. * **Virulence Factors:** S. aureus possesses numerous virulence factors that contribute to its ability to cause pneumonia: * **Toxins:** Alpha-toxin (pore-forming), Panton-Valentine leukocidin (PVL) (causes necrosis and leukocyte destruction), superantigens (e.g., TSST-1) can lead to severe inflammation and toxic shock-like syndromes. * **Enzymes:** Coagulase (forms a protective clot), hyaluronidase (breaks down hyaluronic acid in connective tissue), proteases (degrade host proteins), lipases (damage host cell membranes). * **Adhesins:** Surface proteins like fibronectin-binding proteins promote adherence to host tissues. * **Capsule:** May inhibit phagocytosis. * **Host Immune Response:** The innate immune system, particularly neutrophils, is recruited to the lungs to phagocytose S. aureus. However, S. aureus can evade phagocytosis and can trigger excessive inflammatory responses via its toxins, leading to tissue damage. The adaptive immune response, involving B cells producing antibodies and T cells, develops later. * **Diagnostic Approaches:** Diagnosis relies on clinical presentation, chest imaging (radiograph or CT scan), and laboratory investigations: * **Sputum Gram stain and culture:** Essential for identifying the causative organism and determining antibiotic susceptibility. * **Blood cultures:** Important to rule out bacteremia. * **Complete blood count (CBC):** May show leukocytosis with a neutrophilic predominance. * **Biomarkers:** Procalcitonin can help differentiate bacterial from viral pneumonia and assess severity. Management Principles: * **Antibiotic Therapy:** Prompt initiation of appropriate antibiotic therapy is crucial. For S. aureus CAP, empirical therapy should cover Gram-positive organisms, and given the potential for MRSA, agents with MRSA activity are often considered, especially in severe cases or when risk factors for MRSA are present. * **Susceptible S. aureus (MSSA):** Beta-lactam antibiotics like nafcillin, oxacillin, or cefazolin are typically first-line. Fluoroquinolones or clindamycin can be alternatives. * **Methicillin-Resistant S. aureus (MRSA):** Vancomycin, linezolid, or daptomycin are primary treatment options. * **Duration:** Typically 7-14 days, depending on clinical response and severity. * **Supportive Care:** Oxygen therapy, bronchodilators, and mechanical ventilation if respiratory failure occurs. * **Drainage:** If a lung abscess or empyema develops, surgical drainage may be necessary. Potential Complications: * **Bacteremia and Sepsis:** Spread of infection to the bloodstream. * **Lung Abscess:** Localized collection of pus within the lung parenchyma. * **Empyema:** Pus in the pleural space. * **Pneumothorax:** Air in the pleural space. * **Necrotizing Pneumonia:** Rapid destruction of lung tissue, often associated with PVL-producing strains. * **Respiratory Failure:** Severe impairment of gas exchange.